Assay identified 98% of relapses and 100% of cutaneous melanoma-related deaths in stage IB/IIA patients Patients with stage IB/IIA melanoma identified as high-risk had a relapse rate comparable
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
ROTTERDAM, Netherlands and SAN DIEGO, April 20, 2023 /PRNewswire/ SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and